drugset / Trial / NCT05611372
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
Phase 2/3
Withdrawn
Second Affiliated Hospital, School of Medicine, Zhejiang University
Beijing Tiantan Hospital · collabFujian Medical University Union Hospital · collabGuizhou Medical University · collabHuashan Hospital · collabJiangsu Province Nanjing Brain Hospital · collabQilu Hospital of Shandong University · collabSecond Affiliated Hospital of Soochow University · collabSir Run Run Shaw Hospital · collabThe Affiliated Hospital of Hangzhou Normal University · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabWest China Hospital · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).
Timeline
- Start
- 2023-01-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “No suitable recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rasagiline | Small molecule | 1 mg | — |